Life Sciences Research for Lifelong Health

Jayeta Saxena

Jayeta did her undergraduate studies in Biochemistry at University of Delhi, before moving to UCL for a masters in Molecular Medicine where she developed an interest in cancer while studying glioblastomas for my thesis project. She then worked at UCL Cancer Institute, researching about cancer metabolism in leukemias. Jayeta is currently studying the RAS-RAF-MEK1/2-ERK1/2 signalling pathway to understand the mechanisms of underpinning acquired resistance to cancer chemotherapy. Her outside interests include reading, travelling, classical music, movies (love Bollywood films) and sleeping (she practices this as a hobby).

Latest Publications

RNA-binding proteins ZFP36L1 and ZFP36L2 promote cell quiescence.

Galloway A, Saveliev A, Łukasiak S

Science (New York, N.Y.)
352 1095-9203:453-9 (2016)

PMID: 27102483

Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation.

Lochhead PA, Clark J, Wang LZ

Cell cycle (Georgetown, Tex.)
15 1551-4005:506-18 (2016)

PMID: 26959608

Maternal DNA Methylation Regulates Early Trophoblast Development.

Branco MR, King M, Perez-Garcia V

Developmental cell
36 1878-1551:152-63 (2016)

PMID: 26812015

MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road.

Caunt CJ, Sale MJ, Smith PD

Nature reviews. Cancer
15 1474-1768:577-92 (2015)

PMID: 26399658

Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity of DYRK1B mutants from cancer and metabolic syndrome.

Ashford AL, Dunkley TP, Cockerill M

Cellular and molecular life sciences : CMLS
1420-9071: (2015)

PMID: 26346493

Intrinsic and acquired resistance to MEK1/2 inhibitors in cancer.

Sale MJ, Cook SJ

Biochemical Society transactions
42 1470-8752:776-83 (2014)

PMID: 25109957